333 related articles for article (PubMed ID: 18849168)
41. Rapid hit to lead evaluation of pyrazolo[3,4-d]pyrimidin-4-one as selective and orally bioavailable mGluR1 antagonists.
Wang X; Kolasa T; El Kouhen OF; Chovan LE; Black-Shaefer CL; Wagenaar FL; Garton JA; Moreland RB; Honore P; Lau YY; Dandliker PJ; Brioni JD; Stewart AO
Bioorg Med Chem Lett; 2007 Aug; 17(15):4303-7. PubMed ID: 17532216
[TBL] [Abstract][Full Text] [Related]
42. Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction.
Carroll FI
Ann N Y Acad Sci; 2008 Oct; 1141():221-32. PubMed ID: 18991960
[TBL] [Abstract][Full Text] [Related]
43. Discovery of novel and orally active NR2B-selective N-methyl-D-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity.
Kawai M; Nakamura H; Sakurada I; Shimokawa H; Tanaka H; Matsumizu M; Ando K; Hattori K; Ohta A; Nukui S; Omura A; Kawamura M
Bioorg Med Chem Lett; 2007 Oct; 17(20):5533-6. PubMed ID: 17768047
[TBL] [Abstract][Full Text] [Related]
44. In vitro metabolic studies on the selective metabotropic glutamate receptor sub-type 5 (mGluR5) antagonist 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl]-pyridine (MTEP).
Green MD; Yang X; Cramer M; King CD
Neurosci Lett; 2006 Jan; 391(3):91-5. PubMed ID: 16153770
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: new potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Part 1.
Woltering TJ; Adam G; Alanine A; Wichmann J; Knoflach F; Mutel V; Gatti S
Bioorg Med Chem Lett; 2007 Dec; 17(24):6811-5. PubMed ID: 17964783
[TBL] [Abstract][Full Text] [Related]
46. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.
Laleu B; Gaggini F; Orchard M; Fioraso-Cartier L; Cagnon L; Houngninou-Molango S; Gradia A; Duboux G; Merlot C; Heitz F; Szyndralewiez C; Page P
J Med Chem; 2010 Nov; 53(21):7715-30. PubMed ID: 20942471
[TBL] [Abstract][Full Text] [Related]
47. Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
Roppe J; Smith ND; Huang D; Tehrani L; Wang B; Anderson J; Brodkin J; Chung J; Jiang X; King C; Munoz B; Varney MA; Prasit P; Cosford ND
J Med Chem; 2004 Sep; 47(19):4645-8. PubMed ID: 15341479
[TBL] [Abstract][Full Text] [Related]
48. Dipyridyl amines: potent metabotropic glutamate subtype 5 receptor antagonists.
Kamenecka TM; Bonnefous C; Govek S; Vernier JM; Hutchinson J; Chung J; Reyes-Manalo G; Anderson JJ
Bioorg Med Chem Lett; 2005 Oct; 15(19):4350-3. PubMed ID: 16039855
[TBL] [Abstract][Full Text] [Related]
49. 6-Aryl-3-pyrrolidinylpyridines as mGlu5 receptor negative allosteric modulators.
Weiss JM; Jimenez HN; Li G; April M; Uberti MA; Bacolod MD; Brodbeck RM; Doller D
Bioorg Med Chem Lett; 2011 Aug; 21(16):4891-9. PubMed ID: 21757343
[TBL] [Abstract][Full Text] [Related]
50. Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.
Chua PC; Nagasawa JY; Bleicher LS; Munoz B; Schweiger EJ; Tehrani L; Anderson JJ; Cramer M; Chung J; Green MD; King CD; Reyes-Manalo G; Cosford ND
Bioorg Med Chem Lett; 2005 Oct; 15(20):4589-93. PubMed ID: 16115767
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists.
Wendt JA; Deeter SD; Bove SE; Knauer CS; Brooker RM; Augelli-Szafran CE; Schwarz RD; Kinsora JJ; Kilgore KS
Bioorg Med Chem Lett; 2007 Oct; 17(19):5396-9. PubMed ID: 17723296
[TBL] [Abstract][Full Text] [Related]
52. Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists.
Zheng GZ; Bhatia P; Daanen J; Kolasa T; Patel M; Latshaw S; El Kouhen OF; Chang R; Uchic ME; Miller L; Nakane M; Lehto SG; Honore MP; Moreland RB; Brioni JD; Stewart AO
J Med Chem; 2005 Nov; 48(23):7374-88. PubMed ID: 16279797
[TBL] [Abstract][Full Text] [Related]
53. Novel thienopyrimidinones as mGluR1 antagonists.
Kim Y; Kim J; Kim S; Ki Y; Seo SH; Tae J; Ko MK; Jang HS; Lim EJ; Song C; Cho Y; Koh HY; Chong Y; Choo IH; Keum G; Min SJ; Choo H
Eur J Med Chem; 2014 Oct; 85():629-37. PubMed ID: 25127154
[TBL] [Abstract][Full Text] [Related]
54. Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
Smith ND; Poon SF; Huang D; Green M; King C; Tehrani L; Roppe JR; Chung J; Chapman DP; Cramer M; Cosford ND
Bioorg Med Chem Lett; 2004 Nov; 14(22):5481-4. PubMed ID: 15482908
[TBL] [Abstract][Full Text] [Related]
55. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 2: 4-thiopyridyl acetophenones as non-tetrazole containing mGlu2 receptor potentiators.
Pinkerton AB; Cube RV; Hutchinson JH; James JK; Gardner MF; Schaffhauser H; Rowe BA; Daggett LP; Vernier JM
Bioorg Med Chem Lett; 2004 Dec; 14(23):5867-72. PubMed ID: 15501058
[TBL] [Abstract][Full Text] [Related]
56. Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.
Asada M; Obitsu T; Nagase T; Sugimoto I; Yamaura Y; Sato K; Narita M; Ohuchida S; Nakai H; Toda M
Bioorg Med Chem; 2009 Sep; 17(18):6567-82. PubMed ID: 19700331
[TBL] [Abstract][Full Text] [Related]
57. Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
J Med Chem; 2010 Mar; 53(5):2010-37. PubMed ID: 20141147
[TBL] [Abstract][Full Text] [Related]
58. Structure-activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists.
Gore VK; Ma VV; Tamir R; Gavva NR; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2007 Nov; 17(21):5825-30. PubMed ID: 17851073
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic pain.
Brumfield S; Korakas P; Silverman LS; Tulshian D; Matasi JJ; Qiang L; Bennett CE; Burnett DA; Greenlee WJ; Knutson CE; Wu WL; Sasikumar TK; Domalski M; Bertorelli R; Grilli M; Lozza G; Reggiani A; Li C
Bioorg Med Chem Lett; 2012 Dec; 22(23):7223-6. PubMed ID: 23084894
[TBL] [Abstract][Full Text] [Related]
60. The identification of novel orally active mGluR5 antagonist GSK2210875.
Pilla M; Andreoli M; Tessari M; Delle-Fratte S; Roth A; Butler S; Brown F; Shah P; Bettini E; Cavallini P; Benedetti R; Minick D; Smith P; Tehan B; D'Alessandro P; Lorthioir O; Ball C; Garzya V; Goodacre C; Watson S
Bioorg Med Chem Lett; 2010 Dec; 20(24):7521-4. PubMed ID: 21051228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
